✦ LIBER ✦

HYPOPLASTIC ACUTE LEUKAEMIA: CYTOGENETIC EVIDENCE FOR DIFFERENTIATION IN VIVO IN RESPONSE TO LOW-DOSE ARA-C

✍ Scribed by I. A. G. Reilly; J. Sadler; N. H. Russell

Book ID: 114711262
Publisher: John Wiley and Sons
Year: 1987
Tongue: English
Weight: 231 KB
Volume: 65
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.1987.tb06879.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A predictive model for the clinical resp

A predictive model for the clinical response to low dose ara-C: a study of 102 patients with myelodysplastic syndromes or acute leukaemia

✍ Eva Hellström-Lindberg; Karl-Henrik Robèrt; Gösta Gahrton; Greger Lindberg; Ann- 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 791 KB

Cytogenetic and molecular responses in c

Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose

✍ Massimo Breccia; Laura Cannella; Caterina Stefanizzi; Roberto Latagliata; Mauro 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB

## Abstract Imatinib mesylate is the gold standard treatment of chronic myeloid leukaemia (CML) and 400 mg/day is considered the standard dose. Although it is generally well tolerated, some patients require temporary drug discontinuation and permanent dose reduction because of haematological or non

Low-dose cytosine arabinoside regimen in

Low-dose cytosine arabinoside regimen induced a complete remission with normal karyotypes in a case with hypoplastic acute myeloid leukaemia with No. 8-trisomy: in vitro and in vivo evidence for normal haematopoietic recovery

✍ M. Tagawa; J. Shibata; M. Tomonaga; T. Amenomori; Y. Yoshida; K. Kuriyama; T. Ma 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 438 KB

[NATO Science for Peace and Security Ser

[NATO Science for Peace and Security Series C: Environmental Security] Radiobiology and Environmental Security Volume a || Low Dose Responses of Bone Marrow to X-Rays In Vivo

✍ Mothersill, Carmel E.; Korogodina, Victoria; Seymour, Colin B. 📂 Article 📅 2011 🏛 Springer Netherlands ⚖ 156 KB

Adding low-dose gemtuzumab ozogamicin to

Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients

✍ Marino Clavio; Luana Vignolo; Alessandra Albarello; Riccardo Varaldo; Ivana Pier 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 560 KB